Full-Time

Medical Science Liaison

Sleep

Posted on 9/11/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$154.4k - $231.6k/yr

+ Bonus + Incentive Compensation + Equity Grants

Des Moines, IA, USA + 6 more

More locations: Lincoln, NE, USA | Wichita, KS, USA | Chicago, IL, USA | St. Louis, MO, USA | Kansas City, MO, USA | Omaha, NE, USA

Remote

Candidates must be based in the Midwest region of the United States.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Ability to effectively communicate scientific data to both internal and external customers, including opinion leaders and managed care organizations
  • Knowledge of geography and key opinion leaders preferred
  • Thorough understanding of applicable federal and state regulatory requirements for field-based scientific personnel
  • Demonstrated ability to develop trust and relationships with opinion leaders in disease states of interest
  • Collaborative, team-based approach; ability to network and partner with internal and external stakeholders, including commercial and R&D partners, medical opinion leaders, academic institutions, large group practices, managed care organizations, medical directors and pharmacy directors in institutional practices
  • Ability to work evenings and weekends
  • Ability and willingness to travel 60% of work days
Responsibilities
  • Provide field-based scientific exchange and communication of FDA approved and pipeline products
  • In support of FDA approved products, work within the Medical Science Liaison team’s objectives
  • Identify, establish, and maintain scientific relationships with opinion leaders regarding disease-state and product-specific information
  • Facilitate scientific development of pipeline compounds at research centers, and secure the company’s presence in the designated therapeutic areas
  • Support the clinical operations organization, as needed, in Jazz Pharmaceuticals sponsored research
  • Serve as primary liaison with investigators interested in developing and performing investigator initiated research
  • Cross-functional nature of role requires close alignment with the Medical Affairs, Commercial, and Clinical Development groups
  • Document and forward reports of adverse events according to Jazz’s policy to ensure safe and effective use of Jazz Pharmaceuticals' products
  • Attend and provide scientific support of Medical Affairs activities and scientific sessions at regional and national congress meetings
  • Develop and prioritize solutions to problems, understand relationship between actions and results and able to understand and appreciate needs of customers
  • Proactively seeks out and demonstrates successful peer coaching of other team members
  • Successfully manages at least two large cross-functional projects with demonstrated leadership and collaboration skills while successfully maintaining geographical responsibilities
Desired Qualifications
  • A minimum of 0-2 years of experience in the pharmaceutical industry and/or clinical/research experience (MSL experience preferred)
  • Preference will be given those with experience in Sleep Medicine; however, experience in Neurology, Psychiatry or other relevant backgrounds will be considered

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex generated $1.1B in 2025 sales, up 9% YoY, with patents protected to late 2030s.
  • Q1 2026 revenue hit $1.1B, up 19% YoY, prompting Raymond James target raise to $239 on May 7.
  • Chimerix acquisition adds dordaviprone for H3 K27M-mutant glioma, PDUFA August 18, 2025.

What critics are saying

  • Generic competition erodes Xywav revenue as it replaces Xyrem, decelerating growth to 5.5% annually.
  • Dordaviprone fails FDA approval on August 18, 2025 PDUFA, wasting $935M Chimerix acquisition.
  • $850M exchangeable notes due 2030 dilute equity at $153.05 exchange price amid EPS decline.

What makes Jazz Pharmaceuticals unique

  • Jazz Pharmaceuticals focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Xywav offers 92% less sodium than Xyrem, approved July 21, 2020, for narcolepsy in patients aged 7+.
  • Epidiolex, acquired via $7.2B GW Pharma deal in 2021, treats Lennox-Gastaut and Dravet syndromes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE